Logos Global Management
Latest statistics and disclosures from Logos Global Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IDYA, JANX, RVMD, CYTK, VERA, and represent 33.56% of Logos Global Management's stock portfolio.
- Added to shares of these 10 stocks: BNTX (+$34M), INSM (+$31M), NBIX (+$27M), CYTK (+$24M), IDYA (+$23M), JAZZ (+$22M), BPMC (+$17M), VERA (+$16M), SLNO (+$16M), ALKS (+$14M).
- Started 16 new stock positions in PLRX, INSM, JAZZ, ALKS, Septerna, ACRS, NBIX, DRUG, GERN, BNTX. SLNO, BPMC, APGE, NUVB.WS, AVTE, GLYC.
- Reduced shares in these 10 stocks: IRON (-$47M), CLDX (-$31M), IONS (-$30M), GLPG (-$23M), COGT (-$22M), BCAX (-$20M), IMVT (-$20M), SRPT (-$19M), APLS (-$16M), GPCR (-$15M).
- Sold out of its positions in ADVM, AVTX, BCAX, BEAM, BCYC, BOLD, CLDX, COGT, CMPS, CYBN. ENGN, FULC, GLPG, IOBT, IONS, LCTX, NMRA, NXTC, NUVL, ORKA, RCKT, SRPT, SLN, SKYE.
- Logos Global Management was a net seller of stock by $-18M.
- Logos Global Management has $855M in assets under management (AUM), dropping by -7.79%.
- Central Index Key (CIK): 0001792126
Tip: Access up to 7 years of quarterly data
Positions held by Logos Global Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Logos Global Management
Logos Global Management holds 47 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ideaya Biosciences (IDYA) | 9.0 | $77M | +42% | 3.0M | 25.70 |
|
| Janux Therapeutics (JANX) | 7.8 | $67M | +25% | 1.3M | 53.54 |
|
| Revolution Medicines (RVMD) | 7.4 | $63M | +20% | 1.5M | 43.74 |
|
| Cytokinetics Com New (CYTK) | 5.0 | $42M | +125% | 900k | 47.04 |
|
| Vera Therapeutics Cl A (VERA) | 4.3 | $37M | +75% | 875k | 42.29 |
|
| Biontech Se Sponsored Ads (BNTX) | 4.0 | $34M | NEW | 300k | 113.95 |
|
| Merus N V (MRUS) | 3.7 | $32M | +30% | 750k | 42.05 |
|
| Erasca (ERAS) | 3.7 | $31M | +14% | 13M | 2.51 |
|
| Insmed Com Par $.01 (INSM) | 3.6 | $31M | NEW | 450k | 69.04 |
|
| Ocular Therapeutix (OCUL) | 3.5 | $30M | 3.5M | 8.54 |
|
|
| Neurocrine Biosciences (NBIX) | 3.2 | $27M | NEW | 200k | 136.50 |
|
| Design Therapeutics (DSGN) | 3.0 | $26M | 4.2M | 6.17 |
|
|
| Vaxcyte (PCVX) | 2.9 | $25M | 300k | 81.86 |
|
|
| Akero Therapeutics (AKRO) | 2.6 | $22M | 800k | 27.82 |
|
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.5 | $22M | NEW | 175k | 123.15 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.2 | $19M | -44% | 700k | 27.12 |
|
| Olema Pharmaceuticals (OLMA) | 2.2 | $19M | 3.2M | 5.83 |
|
|
| Blueprint Medicines (BPMC) | 2.0 | $17M | NEW | 200k | 87.22 |
|
| Travere Therapeutics (TVTX) | 2.0 | $17M | -9% | 1.0M | 17.42 |
|
| Apellis Pharmaceuticals (APLS) | 1.9 | $16M | -50% | 500k | 31.91 |
|
| Soleno Therapeutics (SLNO) | 1.8 | $16M | NEW | 350k | 44.95 |
|
| Alkermes SHS (ALKS) | 1.7 | $14M | NEW | 500k | 28.76 |
|
| Apogee Therapeutics (APGE) | 1.6 | $14M | NEW | 300k | 45.30 |
|
| Arvinas Ord (ARVN) | 1.6 | $13M | +75% | 700k | 19.17 |
|
| Annexon (ANNX) | 1.5 | $13M | 2.6M | 5.13 |
|
|
| Disc Medicine (IRON) | 1.5 | $13M | -78% | 200k | 63.40 |
|
| Spyre Therapeutics Com New (SYRE) | 1.4 | $12M | +150% | 500k | 23.28 |
|
| Edgewise Therapeutics (EWTX) | 1.2 | $11M | -11% | 400k | 26.70 |
|
| Dyne Therapeutics (DYN) | 1.2 | $11M | +181% | 450k | 23.56 |
|
| Pliant Therapeutics (PLRX) | 1.2 | $9.9M | NEW | 750k | 13.17 |
|
| Bright Minds Biosciences Com New (DRUG) | 1.0 | $8.8M | NEW | 245k | 36.02 |
|
| Y Mabs Therapeutics (YMAB) | 0.9 | $7.8M | +25% | 1.0M | 7.83 |
|
| Immunovant (IMVT) | 0.9 | $7.4M | -72% | 300k | 24.77 |
|
| Geron Corporation (GERN) | 0.8 | $7.1M | NEW | 2.0M | 3.54 |
|
| Aclaris Therapeutics (ACRS) | 0.6 | $5.5M | NEW | 2.2M | 2.48 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $5.2M | -54% | 1.3M | 4.12 |
|
| Astria Therapeutics (ATXS) | 0.5 | $4.5M | 500k | 8.94 |
|
|
| Unicycive Therapeutics (UNCY) | 0.5 | $4.0M | 5.1M | 0.79 |
|
|
| Aerovate Therapeutics (AVTE) | 0.4 | $3.7M | NEW | 1.4M | 2.65 |
|
| Rapport Therapeutics (RAPP) | 0.4 | $3.7M | 209k | 17.74 |
|
|
| Atyr Pharma Com New (ATYR) | 0.4 | $3.6M | -50% | 1.0M | 3.62 |
|
| Allakos (ALLK) | 0.4 | $3.5M | 2.9M | 1.21 |
|
|
| Enliven Therapeutics (ELVN) | 0.4 | $3.2M | -71% | 140k | 22.50 |
|
| Septerna | 0.4 | $3.1M | NEW | 134k | 22.90 |
|
| Artiva Biotherapeutics (ARTV) | 0.2 | $1.5M | 145k | 10.08 |
|
|
| Glycomimetics (GLYC) | 0.2 | $1.3M | NEW | 5.4M | 0.25 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $15k | NEW | 67k | 0.23 |
|
Past Filings by Logos Global Management
SEC 13F filings are viewable for Logos Global Management going back to 2019
- Logos Global Management 2024 Q4 filed Feb. 14, 2025
- Logos Global Management 2024 Q3 filed Nov. 14, 2024
- Logos Global Management 2024 Q2 amended filed Aug. 27, 2024
- Logos Global Management 2024 Q2 filed Aug. 14, 2024
- Logos Global Management 2024 Q1 filed May 15, 2024
- Logos Global Management 2023 Q4 filed Feb. 14, 2024
- Logos Global Management 2023 Q3 filed Nov. 14, 2023
- Logos Global Management 2023 Q2 filed Aug. 14, 2023
- Logos Global Management 2023 Q1 filed May 15, 2023
- Logos Global Management 2022 Q4 filed Feb. 14, 2023
- Logos Global Management 2022 Q3 filed Nov. 14, 2022
- Logos Global Management 2022 Q2 filed Aug. 15, 2022
- Logos Global Management 2022 Q1 filed May 16, 2022
- Logos Global Management 2021 Q4 filed Feb. 14, 2022
- Logos Global Management 2021 Q3 filed Nov. 15, 2021
- Logos Global Management 2021 Q2 restated filed Aug. 17, 2021